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Kynurenic acidHyperuricemia is related to a variety of pathologies, including chronic kidney disease (CKD). However, the
pathophysiological mechanisms underlying disease development are not yet fully elucidated. Here, we stud-
ied the effect of hyperuricemia on tryptophan metabolism and the potential role herein of two important uric
acid efﬂux transporters, multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP).
Hyperuricemia was induced in mice by treatment with the uricase inhibitor oxonic acid, conﬁrmed by the
presence of urate crystals in the urine of treated animals. A transport assay, using membrane vesicles of
cells overexpressing the transporters, revealed that uric acid inhibited substrate-speciﬁc transport by BCRP
at clinically relevant concentrations (calculated IC50 value: 365 ± 13 μM), as was previously reported for
MRP4. Moreover, we identiﬁed kynurenic acid as a novel substrate for MRP4 and BCRP. This ﬁnding was cor-
roborated by increased plasma levels of kynurenic acid observed in Mrp4−/− (107 ± 19 nM; P = 0.145) and
Bcrp−/− mice (133 ± 10 nM; P = 0.0007) compared to wild type animals (71 ± 11 nM). Hyperuricemia
was associated with >1.5 fold increase in plasma kynurenine levels in all strains. Moreover, hyperuricemia
led to elevated plasma kynurenic acid levels (128 ± 13 nM, P = 0.005) in wild type mice but did not further
increase kynurenic acid levels in knockout mice. Based on our results, we postulate that elevated uric acid
levels hamper MRP4 and BCRP functioning, thereby promoting the retention of other potentially toxic sub-
strates, including kynurenic acid, which could contribute to the development of CKD.
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Uric acid is a weak organic acid and the end-product of purine nu-
cleotides degradation in humans. One of the enzymes involved in this
process is xanthine oxidoreductase, which enables the oxidation of
hypoxanthine to xanthine and can further catalyze the oxidation of
xanthine to uric acid. During this reaction, reactive oxygen species
are generated as by-product [1,2]. Therefore, uric acid is recognized
as a marker for oxidative stress. However, the molecule itself has
antioxidant properties and can act as a free radical scavenger and
chelator of transitional metal ions which are converted into poorly re-
active forms [3]. Hyperuricemia, i.e. elevated plasma uric acid levels
(≥360 μM) [4], is related to a variety of pathologies, including gout,
cardiovascular disease and chronic kidney disease (CKD). Gout is
the most common form of inﬂammatory arthritis caused by sodium
uric acid crystal precipitation, which is followed by phagocytosis of
the crystals by neutrophils and macrophages and activation of acute
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prevalence and incidence are still increasing [6,7]. Formation of uric
acid crystals is also the cause of nephrolithiasis, i.e. kidney stones,
which is signiﬁcantly more common among patients diagnosed with
metabolic syndrome, obesity and type 2 diabetes [8]. Hyperuricemia
also correlates with the development and progression of cardiovascu-
lar diseases [9–11], potentially via interfering with nitric oxide func-
tion. In animal models, it has been shown that mild hyperuricemia
contributes to the development of hypertension as a result of endo-
thelial dysfunction and reduction of nitric oxide levels [10,12,13].
Recently, hyperuricemia has received attention as a possible risk
factor for CKD [4,14], which affects approximately 10% of the adult
population in developed countries [15]. Hyperuricemia has been
associatedwith a hazard ratio of 2.1 and 1.3 formen andwomen for de-
veloping CKD [4], respectively. Several mechanisms were proposed via
which uric acid could contribute to the development of CKD, including
uric acid-induced glomerular hypertrophy and endothelial dysfunction
[4,16]. However, the pathophysiological mechanism has as of yet not
been fully elucidated.
In healthy individuals, two-thirds of uric acid is excreted by the
kidney and one-third by the intestine due to breakdown of urate by
gut bacteria. Purine ingestion, endogenous synthesis of purines from
nonpurine precursors and reutilization of preformed purine com-
pounds are the sources of uric acid production, a process that, under
steady-state conditions, is in balance with the uric acid disposal
[17,18]. Hyperuricemia can develop due to overproduction or a dimin-
ished excretion of uric acid. Maintaining uric acid homeostasis is highly
dependent on kidney function and regulated by a number of transporters,
including the urate transporter 1 (URAT1; SLC22A12) – responsible for up
to 99% of uric acid reabsorption after glomerularﬁltration – the facilitated
glucose transporter (solute carrier family 2 member 9 (SLC2A9))
[19], several organic anion transporters including OAT1 (SLC22A6)
and OAT3 (SLC22A8) [5], and the ATP-dependent urate efﬂux trans-
porters multidrug resistance protein 4 (MRP4; ABCC4) [20] and
breast cancer resistance protein (BCRP; ABCG2) [21–23].
As uric acid is one of the important factors in a variety of patholo-
gies, tight regulation of this metabolite is of key importance. The vital
role of transporters in uric acid homeostasis can clearly be observed
in patients suffering from hyperuricemia due to single nucleotide
polymorphisms (SNPs) that render the transporters inactive, such as
the common SNP C421A encoding the Q141K mutation of BCRP
[21,22,24] and several genetic variants for SLC2A9 [19]. Next to genet-
ic factors, high plasma levels of uric acid might also result in a reduced
transporter activity [20]. Since these transporters are also involved in
the excretion of a wide variety of other compounds, changes in trans-
port efﬁcacy could result in metabolic disturbances. This hypothesis is
corroborated by two recent studies showing that high uric acid levels
in patients with acute gout were associated with altered tryptophan
concentrations in plasma and urine [25,26]. Therefore, the aim of our
study was to investigate the effect of hyperuricemia on tryptophanme-
tabolism and the potential role herein of two important uric acid efﬂux
transporters, MRP4 and BCRP. Both transporters are expressed in the
apical membrane of renal proximal tubule cells, amongst other tissues,
and are involved in the urinary excretion of a multitude of endogenous
compounds and drugs [27]. Using Mrp4−/− and Bcrp−/− mice, we
show that hyperuricemia is associated with the accumulation of
tryptophan and associated metabolites, most likely due to transporter
dysfunction.
2. Material and methods
2.1. Transduction of human embryonic kidney cells and preparation of
membrane vesicles
Overexpression of MRP4 and BCRP in human embryonic kidney
cells (HEK293; American Type Culture Collection, Manassas, VA) wasestablished using baculoviruses, which were produced using the
Bac-to-Bac and the Gateway system (Invitrogen, The Netherlands),
as described previously [28,29]. As a control, the enhanced yellow
ﬂuorescent protein (eYFP) was introduced as mock protein into the
baculovirus expression system. Crude membranes of HEK293-MRP4,
-BCRP and -mock cells were isolated, resuspended in TS buffer
(10 mMTris–HEPES and 250 mM sucrose, pH 7.4) andmembrane ves-
icles were prepared according to a previously describedmethod [28] by
means of ultracentrifugation. Crudemembrane vesicles were dispensed
in aliquots, snap frozen in liquid nitrogen, and stored at −80 °C until
further use.
2.2. Membrane vesicle inhibition and uptake assays
The effects of uric acid and oxonic acid on MRP4 and/or BCRP ac-
tivity were assessed by a well-established assay in our laboratory
[28–31]. In brief, a reaction mix consisting of TS buffer supplemented
with 4 mM ATP/AMP, 10 mMMgCl2 and 250 nM [3H]-methotrexate
(MTX; for MRP4) or [3H]-estrone sulphate (E1S; for BCRP) at pH 7.4
was added to 7.5 μg of membrane vesicles (based on total protein
content). After incubation at 37 °C to enable ATP-dependent uptake,
the reaction was stopped by placing the samples on ice and by addi-
tion of ice-cold TS buffer. Reaction mix was removed and the vesicles
were washed by means of a rapid ﬁltration technique using ﬁlter
plates (Millipore, Etten-Leur, The Netherlands). Scintillation ﬂuid was
added to the ﬁlters and the amount of radioactivity was determined
using a scintillation counter (Tri-Carb® 2900TR; Perkin Elmer, Waltham,
MA, USA). Reference samples were measured to calculate the amount of
transported MTX and E1S. ATP-dependent transport was calculated by
subtracting values measured in the presence of AMP from those mea-
sured in the presence of ATP. Net transporter-mediated substrate uptake
was calculated by subtracting ATP-dependent uptake in HEK293-mock
vesicles from that of HEK293-transporter vesicles.
Uptake of kynurenic acid intoMRP4-overexpressingmembrane ves-
icles was established using the same assay. Vesicles were incubated
with 0.1 mM kynurenic acid in the presence of AMP or ATP. After the
described washing step, kynurenic acid was determined by LC–MS/MS.
2.3. Oxonic acid-mediated induction of hyperuricemia in mice
All experiments were approved by the local Animal Welfare Com-
mittee of the Radboud University Nijmegen Medical Centre (RU-DEC
2012-018), in accordance with the directive for animal experiments
(2010/63/EU) of the European Parliament. The effects of hyperurice-
mia in vivo were examined in wild type (WT) Friend leukemia virus
B (FVB) mice as well as Mrp4−/− and Bcrp−/− mice (both FVB
background). The WT FVB and Bcrp−/− mice were kindly provided
by Dr. A. Schinkel (Netherlands Cancer Institute, Amsterdam, The
Netherlands) and the Mrp4−/− mice by Dr. J. Schuetz (St. Jude
Children's Research Hospital, Memphis, TN, USA) and Dr. P. Borst
(Netherlands Cancer Institute, Amsterdam, The Netherlands), all
animals were bred and housed at the Central Animal Laboratory of
the RUNMC. The animals (N = 9) received the uricase inhibitor
oxonic acid (2% w/v; pH 7) via their drinking water, ad libitum, to
induce hyperuricemia [32]. The animals were individually caged and
housed under controlled conditions. Parallel control groups were
also individually caged and received normal tap water at equal pH.
After 14 days, mice were placed individually in metabolic cages
(Techniplast, Germany GmbH) to collect 24 h urine samples, with ac-
cess to water (with or without oxonic acid 2% w/v) and pulverized
standard chow ad libitum. Next, blood was collected from the orbital
sinus in lithium–heparin tubes via a terminal procedure performed
under isoﬂurane anesthesia and centrifuged for 15 min at 3000 ×g
to obtain plasma. Animals were sacriﬁced by cervical dislocation.
Isolated kidneys, plasma and urine were immediately snap frozen in
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ical parameters were determined by routine clinical chemistry.2.4. Energy-dispersive X-ray (EDX) microanalysis
Transmission electron microscopy and EDX were performed for
identiﬁcation of the ultrastructure and composition of the insoluble
crystals found in the urine samples of oxonic acid-treated mice.
Urine samples were spotted onto copper grids (100 mesh) coated
with a support ﬁlm, air dried, negative stained with uranyl acetate
and examined using a Jeol 1200 EX II. For EDX measurements, the
grids were examined using a Jeol 1200/STEM in combination with
a Thermo Noran microanalysis six system. Accelerated voltage of
60 keV was used for X-ray microanalysis. X-ray spectra for element
distribution were acquired. In each sample, 3–5 measuring points
were selected.2.5. RNA isolation and quantitative PCR
Effects of hyperuricemia on kidney injury was evaluated by deter-
mining mRNA expression levels of early renal injury markers kidney in-
jury molecule-1 (Kim-1) and neutrophil gelatinase-associated lipocalin
(Ngal) in kidneys of treated and control mice. Frozen kidneys were ho-
mogenized using a Mikro-dismembrator U (Sartorius B. Braun Biotech
Int., Melsungen, Germany). Subsequently, total RNA was isolated using
a NucleoSpin® RNA II kit (Macherey-Nagel, Düren, Germany) according
to manufacturer's instructions. Immediately, a reverse transcriptase
reaction was performed with 250 ng RNA using random primers
(Invitrogen, Breda, TheNetherlands) and anOmniscript®RT kit (Qiagen,
Hilden, Germany), following manufacturer's recommendations. Syn-
thesized cDNA was used for quantitative PCR, performed in a
StepOnePlus™ Real-Time PCR system bymeans of the TaqMan® pro-
tocol (Applied Biosystems, Warrington, UK). Kim-1 and Ngal mRNA
concentrations were normalized to the mRNA concentration of the
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (Gapdh).
The primer-probe sets were obtained from Applied Biosystems (Gapdh;
Mm999999915_g1, Kim-1; havcr1 Mm00506686_m1, Ngal; lcn2
Mm01324470_m1).2.6. Tryptophan, kynurenine and kynurenic acid measurements by
LC–MS/MS
After the vesicle uptake experiments, kynurenic acid was extracted
from the ﬁlters in 3.3% perchloric acid. Plasma samples were diluted in
H2O (1:1) prior to LC–MS/MS measurements and deproteinized with
perchloric acid (ﬁnal concentration 3.3%). Samples were centrifuged at
12,000 ×g for 3 min. Clear supernatant was injected into the
LC–MS/MS system that consisted of an Accela HPLC system (Thermo
scientiﬁc, Breda, The Netherlands) equipped with a C18 HPLC column
(VisionHT C18 B 10,062 mm, 1.5 mm; Grace). Tryptophan, kynurenine
and kynurenic acid were measured in the same run. Deuterated
kynurenic acid was added as an internal standard for quantiﬁcation.
Measurements were performed as published earlier [30].2.7. Kinetic analysis and statistics
Statistics were performed using GraphPad Prism 5.02 via one-way
analysis of variance (ANOVA) followed by the Dunnett's Multiple
Comparison Test to study differences between all groups as well as
an unpaired Student's t-test to study the impact of oxonic acid treat-
ment within each strain. Differences between groups were consid-
ered to be statistically signiﬁcant when P b 0.05. GraphPad Prism
was also used to perform non-linear regression analysis.3. Results
3.1. Oxonic acid induces hyperuricemia
To study the impact of hyperuricemia on murine physiology, wild
type (WT), Mrp4−/− and Bcrp−/−mice were treated with the uricase
inhibitor oxonic acid as described before [32]. Two weeks of oxonic
acid treatment did neither affect overall weight of the mice, nor plas-
ma levels of urea, sodium and calcium (Table 1). Interestingly, water
intake was strongly increased after oxonic acid treatment in all
strains investigated, with an increase up to four times that of controls
in Bcrp-deﬁcient mice. This was accompanied by a two-fold increase
in urine ﬂow in treated WT animals; whereas no signiﬁcant changes
were observed in knockout animals. Yet baseline urine ﬂow of
Bcrp−/− mice tended to be increased as compared to WT animals.
Following oxonic acid treatment, the urine collected from all animals
was turbid due to presence of crystals (Fig. 1A–D). Energy-dispersive
X-ray microanalysis (EDX) revealed that the major constituents of the
urinary crystals were sodium, potassium, phosphorus and calcium; the
copper signals arose from the sample grid used in the analysis
(Fig. 1E). Two types of crystals could be distinguished: ﬁrst, crystals
that showed an archetypical peak pattern corresponding to uric acid
crystals, which consisted primarily of sodium, calcium and phosphorus
(Fig. 1F). Second, crystals that mainly contained calcium and potassium
(Fig. 1G), which was likely due to the treatment with oxonic acid potas-
sium salt. These data are in accordance with the development of hyper-
uricemia in oxonic acid-treated mice.
3.2. Uric acid inhibits BCRP activity
Plasma urate levels are controlled by an interplay of transporters
expressed in the kidney proximal tubules. MRP4 and BCRP have been
associatedwith active urinary urate efﬂux, andMRP4was also sensitive
to inhibition by urate [20]. We determined the inhibitory properties
of uric acid on BCRP activity using membrane vesicles prepared
from BCRP-overexpressing HEK293 cells. Uric acid dose-dependently
inhibited BCRP-mediated uptake of the substrate E1S (Fig. 2A) with a
calculated half maximal inhibitory concentration (IC50) value of
365 ± 13 μM. Complete inhibition of BCRP activity was found at the
highest uric acid concentration used (i.e. 1 mM). These ﬁndings indi-
cate that uric acid can reduce transport activity of two important efﬂux
pumps at concentrations demonstrated in patients with hyperuricemia
(≥360 μM).
3.3. MRP4-mediated transport of kynurenic acid
There is some evidence linking hyperuricemia to changes in tryp-
tophan levels [25]. In addition, we recently reported that kynurenic
acid, a tryptophan derivative, can interact with MRP4 and BCRP
[30], and we identiﬁed kynurenic acid as a BCRP substrate (Dankers
et al., submitted for publication). Here, we investigated whether
kynurenic acid is also a substrate for MRP4. Fig. 2B shows that the
ATP-dependent uptake of kynurenic acid in MRP4-overexpressing
vesicles is 7-fold higher as compared to controls with an average
rate of 21.6 pmol/mg ∗ min−1. Furthermore, Fig. 2B demonstrates
that non-speciﬁc, AMP-dependent, uptake is very low. These results
indicate that kynurenic acid is indeed transported by MRP4.
3.4. Retention of tryptophan and its metabolites during hyperuricemia
As uric acid can inhibit MRP4 and BCRP-mediated transport and
kynurenic acid is a substrate for both pumps, we determined the
effects of hyperuricemia on tryptophan metabolism and the role of
the efﬂux pumps herein. Plasma tryptophan levels were similar in
all untreated groups, but oxonic acid treatment led to increased tryp-
tophan levels in Mrp4−/− mice (125 μM) as compared to untreated
Table 1
General characteristics and serum and urine biochemistry of experimental groups.
WT WT + oxonic acid Mrp4−/− Mrp4−/− + oxonic acid Bcrp−/− Brcp−/− + oxonic acid
General characteristics
Weight d.0 (g) 22.4 ± 0.8 25.3 ± 1.1 23.4 ± 1.4 25.0 ± 1.5 23.8 ± 1.1 25.7 ± 1.0
Weight d.14 (g) 24.6 ± 1.0 24.9 ± 1.2 23.5 ± 0.9 24.6 ± 0.9 24.5 ± 0.7 24.6 ± 0.6
Water intake (ml/24 h) 1.6 ± 0.4 5.5 ± 0.8*** 2.9 ± 0.6 5.5 ± 1.0* 2.1 ± 0.7 8.5 ± 0.5***
Urine ﬂow (ml/24 h) 0.3 ± 0.1 0.6 ± 0.1* 0.3 ± 0.1 0.7 ± 0.3 0.7 ± 0.2 0.7 ± 0.1
Plasma
Urea (mM) 12.5 ± 0.8 11.8 ± 0.7 11.4 ± 0.4 10.5 ± 0.5 12.5 ± 0.5 11.7 ± 0.6
Sodium (mM) 149.7 ± 1.1 151.1 ± 1.4 147.6 ± 1.8 151.7 ± 0.8 149.4 ± 0.9 148.0 ± 1.0
Calcium (mM) 2.3 ± 0.02 2.4 ± 0.03 2.2 ± 0.02 2.3 ± 0.02 2.3 ± 0.01 2.3 ± 0.02
Urine
Creatinine (μmol/24 h) 1.4 ± 0.6 1.6 ± 0.2 1.1 ± 0.2 1.5 ± 0.3 2.4 ± 0.8 1.3 ± 0.3
Sodium (μmol/24 h) 139.7 ± 63.1 126.3 ± 14.1 93.4 ± 17.4 150.8 ± 42.7 196.0 ± 49.2 138.8 ± 21.4
Individually caged mice were treated with oxonic acid via their drinking water for 14 days. Mice were weighed before and after treatment period. Water intake, urine ﬂow and
urine content were determined after a 24 h-period in metabolic cages at day 14. Plasma was collected at day 14. Data represent mean ± SEM of 9 mice per group. *P b 0.05
and ***P b 0.001 compared to untreated mice from the same strain using a Student's t-test. Differences between the strains were not signiﬁcant (one-way ANOVA).
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tryptophan metabolite, kynurenine, were similar in knockout animals
as compared to WT animals. And oxonic acid treatment led to a
>1.5-fold increase in kynurenine plasma levels in all three strains,
without differences between strains. In contrast, baseline plasma
kynurenic acid levels of knockout mice were elevated compared to
WT mice, which was signiﬁcant for Bcrp−/− mice. Hyperuricemia
did not further increase plasma kynurenic acid levels in knockout
mice, but led to signiﬁcantly elevated levels in WT animals to the
levels of untreated knockout mice. Furthermore, IDO activity, repre-
sented by the ratio between tryptophan and kynurenine, was similar
in untreated strains, but signiﬁcantly increased after oxonic acid
treatment in Bcrp−/− mice (0.5 vs 0.7). Thus, hyperuricemia clearly
affects tryptophan metabolism.
3.5. Oxonic acid does not inﬂuence MRP4 and BCRP activity
To exclude the possibility that oxonic acid itself inhibited the
efﬂux pumps resulting in metabolite retention, we investigated theFig. 1. Analysis of urine samples of WT, Mrp4−/− and Bcrp−/−mice after 14 days of treatmen
untreated animal (A, left and B) and turbid, crystal-ﬁlled urine of an oxonic acid-treated an
The contents of the insoluble crystals were determined by energy dispersive X-ray microana
of all urinary crystals of three oxonic acid-treated WT mice were depicted as mean + SEM
spectrum of urate crystals, containing sodium, calcium and phosphorus, is depicted in pan
calcium and potassium.effect of oxonic acid on MRP4 and BCRP transport activity. Membrane
vesicle uptake studies revealed that oxonic acid itself did not affect
MRP4-mediated MTX uptake and BCRP-mediated E1S uptake with
more than 15% in a concentration range of 1 μM to 1000 μM (Fig. 4).
3.6. Hyperuricemia induces expression of the early kidney injury marker
Ngal
Finally, we studied whether hyperuricemia and changes in trypto-
phan metabolism coincided with an amelioration of kidney function.
Renal damage was evaluated by assessing mRNA expression of the
early renal injury markers Kim-1 and Ngal in kidneys of treated and
control mice. As shown in Fig. 5A, Kim-1 was not differentially
expressed in oxonic acid-treated mice compared to untreated mice.
In contrast, renal Ngal expression (Fig. 5B) was increased after oxonic
acid-induced hyperuricemia. These increases were signiﬁcant for
both knockout strains, and in Mrp4−/− mice expression levels rose
up to 2.3 times that of untreated mice. With regard to kidney func-
tion, no signiﬁcant effect was observed on creatinine and sodiumt with oxonic acid via their drinking water. A representative sample of clear urine of an
imal (A, right and C) is shown by a photograph and micrographs (magniﬁcation 10×).
lysis (EDX). In each sample, 3–5 measuring points were selected (D). The components
of twelve measurements (E). Mainly two types of crystals were found. A typical EDX
el F, while panel G represents an EDX spectrum of oxonic acid crystals consisting of
Fig. 2. Concentration-dependent inhibition of net BCRP-mediated [3H]-estrone sulphate (E1S) uptake by uric acid and MRP4-mediated kynurenic acid uptake into membrane ves-
icles. (A) Membrane vesicles were incubated with 250 nM E1S and increasing concentrations of uric acid in the presence of AMP or ATP, for 60 s at 37 °C. Net BCRP-mediated E1S
uptake was calculated by subtraction of corresponding mock values. Curve ﬁtting was performed by non-linear regression analysis using GraphPad Prism software (version 5.02,
GraphPad Software Inc., San Diego, CA, USA). Graph represents means ± SEM of three independent experiments. (B) Kynurenic acid uptake was assessed by LC–MS/MS analysis
after incubating membrane vesicles with 0.1 mM kynurenic acid in the presence of AMP or ATP, for 5 min at 37 °C. Bars represent mean + SEM of three independent experiments.
***P b 0.001 compared to other bars by one-way ANOVA followed by Dunnett's post-hoc test.
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which was conﬁrmed by histology. Light microscopic evaluation of
HE-stained kidney slices (Fig. 5C) revealed intact brush borders and
absence of casts or destroyed tubules in exposed animals. Taken to-
gether, these results indicate that two weeks of oxonic acid-induced
hyperuricemia reveals, at most, early signs of kidney damage.
4. Discussion
This study reports for the ﬁrst time that hyperuricemia is associat-
ed with disturbances in tryptophan metabolism, most likely due to
uric acid-induced dysfunction of the renal efﬂux pumps MRP4 and
BCRP. High levels of uric acid are associated with an increased risk
for the development of various diseases and the common mode of
action is the formation of crystals (e.g. gout and nephrolithiasis) orFig. 3. Plasma tryptophan metabolism in WT, Mrp4−/− en Bcrp−/−mice. Plasma tryptophan
acid-treated (black) WT, Mrp4−/− en Bcrp−/−mice after 14 days of treatment via drinking w
kynurenine and tryptophan ∗ 100. Bars represent mean + SEM of 9 mice per group. Stati
Multiple Comparison Test and an unpaired Student's t-test. *P b 0.05 and **P b 0.01 by Stuby negatively inﬂuencing the endothelium (e.g. hypertension). Here,
we hypothesized that hyperuricemia could also contribute to disease
development in an indirect manner by promoting the retention of
other potentially toxic metabolites. Our results revealed that oxonic
acid-induced hyperuricemia resulted in elevated plasma levels of
tryptophan, kynurenine and kynurenic acid in vivo. The ﬁndings are
in agreement with two recent studies by Liu et al. [25,26], who
reported that plasma levels of tryptophan were increased in patients
with acute gout while their urinary concentrations were decreased.
Hence, there appears to be a link between hyperuricemia and distur-
bances in tryptophan metabolism.
The efﬂux transporters MRP4 and BCRP are important in regulat-
ing uric acid levels, but also essential for the clearance of many exog-
enous and endogenous waste products. Recently, we demonstrated
that kynurenic acid could interact with MRP4 and BCRP activity in, kynurenine and kynurenic acid levels and IDO activity of untreated (gray) and oxonic
ater, determined by LC–MS/MS analysis. IDO activity is expressed as the ratio between
stical analysis was performed using both one-way ANOVA followed by the Dunnett's
dent's t-test and #P b 0.001 by one-way ANOVA.
Fig. 4. Oxonic acid does not interfere with MRP4-mediated MTX uptake and BCRP-mediated E1S uptake. Membrane vesicles were incubated with 250 nM [3H]-MTX or [3H]-E1S and
indicated concentrations of oxonic acid for 5 min at 37 °C in the presence of AMP or ATP. AMP values were subtracted from ATP values. Net transporter-mediated uptake was
expressed as means + SEM of triplicate measurements in a representative experiment. Results were analyzed by one-way ANOVA followed by Dunnett's post-hoc test.
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is a possible substrate for both transporters [30]. Using the same
assay, we have shown that kynurenic acid is indeed transported by
BCRP (Dankers et al., submitted for publication) and here we report
that kynurenic acid is also a substrate for MRP4. These ﬁndings are
in agreement with the observed increase in plasma kynurenic acid
levels in Mrp4−/− and Bcrp−/− mice. Therefore, MRP4 and BCRP
could be potential novel therapeutic targets for the regulation of
kynurenic acid levels in a variety of diseases.
Kynurenic acid is a widely studied antagonist of the N-methyl-D-
aspartate-receptor and the α7-nicotinic acetylcholine receptor, andFig. 5. Expression of kidney injury markers and histology after oxonic acid treatment. Relati
tissue of untreated (gray) and oxonic acid-treated (black) mice obtained by QPCR. Animals
values were normalized for the endogenous reference gene Gapdh and expressed as mean
Both genes were not differentially expressed in untreated animals of the different strains
shows that no kidney damage was observed in oxonic acid-treated mice (HE staining), whelevated levels of kynurenic acid are related to several neurological
disorders [33]. Another target of kynurenic acid is the orphan
G-protein-coupled receptor GPR35, of which kynurenic acid is one of
the most potent endogenous agonists currently known. The receptor
is highly expressed in the intestine and in several immune cells, includ-
ingmonocytes and T cells. Kynurenic acid also alters the release of mul-
tiple growth factors such as nerve growth factor and ﬁbroblast growth
factor-1 [34]. Thus, perturbations in kynurenic acid levels can result in
marked effects on receptor activation and changes in growth factors.
With regard to pathophysiological effects, classic experiments have
demonstrated that kynurenic acid inhibited pro-insulin synthesis inve mRNA expression levels of kidney injury markers Kim-1 (A) and Ngal (B) in kidney
were exposed to oxonic acid via their drinking water for 14 days. Cycle threshold (Ct)
fold difference from untreated animals + SEM (N = 9). *P b 0.05 by Student's t-test.
. Panel C depicts a representative micrograph of an oxonic acid-treated WT mice and
ich was comparable in treated knockout mice.
1721A.C.A. Dankers et al. / Biochimica et Biophysica Acta 1832 (2013) 1715–1722isolated rat pancreatic islets and increased the release of insulin in rats,
suggesting a role in diabetes [35,36]. Furthermore, in CKD patients,
kynurenic acid accumulates [30] and increased levels correlate pos-
itively to multiple markers of endothelial dysfunction, namely von
Willebrand factor, thrombomodulin and soluble adhesionmolecules
(sICAM-1, sVCAM-1) [37,38]. In addition, kynurenic acid is sug-
gested to be an important early mediator of leukocyte recruitment
[39]. Moreover, kynurenic acid reduces glucuronidation activity of
UDP-glucuronosyltransferases, as shown in proximal tubule cells,
thereby affecting the metabolic capacity of the kidney [40]. Hence, ele-
vated levels of kynurenic acid induced by hyperuricemia, as observed in
our study, might play a pivotal role in the pathophysiological effects
currently attributed to uric acid.
Our results further demonstrated that kynurenine levels were
similar in untreated WT and knockout animals, suggesting that the
levels of this metabolite are not inﬂuenced by MRP4 and BCRP activ-
ity. Following induction of hyperuricemia, kynurenine levels were
markedly increased in all groups. The observed increase might be
due to a reduced activity of a uric acid transporter other than MRP4
and BCRP, elevated tryptophan levels, as seen in Mrp4−/− mice,
and/or increased activity of indoleamine 2,3-dioxygenase (IDO), as
observed in Bcrp−/− mice. Interestingly, IDO is involved in immune
regulation and enzyme activity is higher during chronic inﬂammation
and in CKD patients [41]. The exact interaction between hyperuricemia
and IDO requires further investigation. For a long time, kynurenine was
regarded as an intermediate of tryptophan metabolism with little
biological activity. Yet Opitz et al. [42] recently demonstrated that this
metabolite is a ligand for the aryl hydrocarbon receptor (AHR) and
can promote tumor cell survival and suppress antitumor immune
responses. The AHR signaling pathway is involved in a myriad of cel-
lular processes, including embryogenesis, inﬂammation and phase I
and phase II metabolism. Fascinatingly, another tryptophan metabo-
lite, indoxyl sulphate, is also reported to activate the AHR in primary
human hepatocytes and human umbilical vein endothelial cells
[43,44]. Thus, by disturbing tryptophan metabolism, hyperuricemia
could indirectly be involved in AHR activation and subsequent
pathologies.
Several polymorphisms in transporter genes are associated with ele-
vated serumuric acid levels. For instance,Woodward et al. [22], described
that the common single nucleotide polymorphism (SNP) rs2231142
encoding the Q141K mutation of BCRP caused hyperuricemia-based
gout. Also in a Japanese population, Q141K was shown to be a common
dysfunctional form of BCRP causing gout [21]. Another transporter
recently implicated in uric acid metabolism is SLC2A9. Using Xenopus
oocytes, Vitart et al. [19] demonstrated that SLC2A9-mediated uptake of
uric acid was sevenfold higher in SLC2A9-expressing oocytes compared
to URAT1-expressing oocytes. These ﬁndings have been conﬁrmed by
others [10,45]. Moreover, multiple genome-wide association studies
reported a relationship between uric acid levels and SNPs in several
transporters including SLC17A3, SLC22A11 and SLC22A12 [23,46,47].
Taken together, when studying the link between uric acid and disease
progression it is important to take into consideration the presence of
possible polymorphisms in transporter genes as well as changes in
metabolite levels of transporter-speciﬁc substrates.
Two weeks of hyperuricemia induced early signs of kidney
damage, as observed by an increased mRNA expression of Ngal in
knockout animals. In contrast, no signs of renal damage were seen
in WT animals. These ﬁndings suggest that knockout animals were
more prone to the development of renal failure. Since, kynurenic
acid levels were already elevated in Mrp4−/− and Bcrp−/− animals
before the induction of hyperuricemia, one could argue that other
tryptophan metabolites are responsible for induction of Ngal ob-
served in knockout mice. To better understand the effect of hyperuri-
cemia on the development of CKD, future studies should include
longer treatment periods (>2 weeks) and also determine the levels
of other intermediates and end-products of tryptophan metabolism.In conclusion, our results showed that uric acid dose-dependently
inhibited BCRP activity and inhibition occurred at physiologically rel-
evant levels as was reported previously for MRP4 [20]. Moreover, we
demonstrated that Mrp4- and Bcrp-deﬁciency as well as hyperurice-
mia are associated with alterations in tryptophan metabolism and
the retention of kynurenine and kynurenic acid, two metabolites
with a broad array of biological activities. Therefore, we postulate
that elevated uric acid levels hamper MRP4 and BCRP functioning,
thereby promoting the retention of other potentially toxic substrates,
including kynurenic acid, which could contribute to the development
of CKD. These ﬁndings underline the complex relation between
hyperuricemia and linked pathologies, which should be taken into ac-
count when interpreting results obtained using in vivo hyperuricemia
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